Related Experiment Videos
[Arterial permeability, objective of thrombolytic therapy]
J P Bassand1, F Schiele, Y Bernard
1Service de cardiologie, CHU Saint-Jacques, Besançon.
Archives Des Maladies Du Coeur Et Des Vaisseaux
|May 1, 1992
Summary
Assessing coronary arterial reperfusion timing is crucial for acute myocardial infarction treatment efficacy. Early patency assessments are inaccurate; evaluating the reperfusion rate and plateau phase provides a better measure of thrombolytic drug performance.
Area of Science:
- Cardiology
- Pharmacology
- Interventional Cardiology
Background:
- Thrombolytic therapy for acute myocardial infarction (AMI) primarily relies on coronary arterial reperfusion.
- Myocardial salvage, left ventricular function, and mortality reduction are directly influenced by successful reperfusion.
- Traditional 90-minute patency assessment is inaccurate as reperfusion is a time-dependent, progressive phenomenon.
Purpose of the Study:
- To evaluate the accuracy of traditional patency assessment methods in thrombolytic therapy for AMI.
- To analyze the influence of different thrombolytic agents and administration rates on reperfusion dynamics.
- To compare the efficacy of various thrombolytic drugs, considering reperfusion rate, plateau phase, and reocclusion.
Main Methods:
- Analysis of coronary arterial patency rates over time following thrombolytic administration.
- Comparison of reperfusion rates and plateau phases for different thrombolytic agents, including Streptokinase and rt-PA.
- Assessment of reocclusion rates using coronary angiography between 24 and 72 hours post-treatment.
Main Results:
- Coronary patency increases progressively, reaching a plateau between 4-6 hours and maximal patency at 24-48 hours.
- Streptokinase shows a lower reperfusion rate compared to newer agents and is less effective on chronic thrombi.
- Reocclusion rates are lower with non-fibrin-specific agents (e.g., APSAC, Streptokinase, pro-urokinase) than with rt-PA.
Conclusions:
- Assessing thrombolytic efficacy solely at 90 minutes is inaccurate; the rate and plateau of reperfusion are critical.
- Different thrombolytic agents exhibit varying reperfusion dynamics and reocclusion rates.
- Future strategies involving advanced antiplatelet/antithrombin agents or novel thrombolytic combinations may reduce reocclusion and improve therapy.